1. History of COVID-19 illness diagnosed by RT-PCR/Rapid antigen/ Truenaat of throat or nasopharyngeal swab at least 8 weeks prior <br/ >2. Having persistent respiratory symptoms (cough and breathlessness) or persistent hypoxemia (SpO2 <94% on room air) or oxygen desaturation on exercise <br/ >AND <br/ >Has evidence of pulmonary fibrosis on HRCT thorax (at least 15% involvement by visual semi-quantitative assessment) performed at least 8 weeks after COVID-19 diagnosis <br/ >3. Provides written informed consent for evaluation and treatment as per study protocol <br/ >

1. History of COVID-19 illness diagnosed by RT-PCR/Rapid antigen/ Truenaat of throat or nasopharyngeal swab at least 8 weeks prior <br/ >2. Having persistent respiratory symptoms (cough and breathlessness) or persistent hypoxemia (SpO2 <94% on room air) or oxygen desaturation on exercise <br/ >AND <br/ >Has evidence of pulmonary fibrosis on HRCT thorax (at least 15% involvement by visual semi-quantitative assessment) performed at least 8 weeks after COVID-19 diagnosis <br/ >3. Provides written informed consent for evaluation and treatment as per study protocol <br/ >

1. History of COVID-19 illness diagnosed by RT-PCR/Rapid antigen/ Truenaat of throat or nasopharyngeal swab at least 8 weeks prior <br/ >2. Having persistent respiratory symptoms (cough and breathlessness) or persistent hypoxemia (SpO2 <94% on room air) or oxygen desaturation on exercise <br/ >AND <br/ >Has evidence of pulmonary fibrosis on HRCT thorax (at least 15% involvement by visual semi-quantitative assessment) performed at least 8 weeks after COVID-19 diagnosis <br/ >3. Provides written informed consent for evaluation and treatment as per study protocol <br/ >

1. History of COVID-19 illness diagnosed by RT-PCR/Rapid antigen/ Truenaat of throat or nasopharyngeal swab at least 8 weeks prior <br/ >2. Having persistent respiratory symptoms (cough and breathlessness) or persistent hypoxemia (SpO2 <94% on room air) or oxygen desaturation on exercise <br/ >AND <br/ >Has evidence of pulmonary fibrosis on HRCT thorax (at least 15% involvement by visual semi-quantitative assessment) performed at least 8 weeks after COVID-19 diagnosis <br/ >3. Provides written informed consent for evaluation and treatment as per study protocol <br/ >